181 related articles for article (PubMed ID: 28368376)
1. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.
Khimani F; Kim J; Chen L; Dean E; Rizk V; Betts B; Nishihori T; Locke F; Mishra A; Perez L; Ayala E; Kharfan-Dabaja M; Nieder M; Fernandez H; Anasetti C; Pidala J
Bone Marrow Transplant; 2017 Jul; 52(7):1003-1009. PubMed ID: 28368376
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.
Cutler C; Logan B; Nakamura R; Johnston L; Choi S; Porter D; Hogan WJ; Pasquini M; MacMillan ML; Hsu JW; Waller EK; Grupp S; McCarthy P; Wu J; Hu ZH; Carter SL; Horowitz MM; Antin JH
Blood; 2014 Aug; 124(8):1372-7. PubMed ID: 24982504
[TBL] [Abstract][Full Text] [Related]
4. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
Labrador J; López-Corral L; López-Godino O; Vázquez L; Cabrero-Calvo M; Pérez-López R; Díez-Campelo M; Sánchez-Guijo F; Pérez-López E; Guerrero C; Alberca I; Del Cañizo MC; Pérez-Simón JA; González-Porras JR; Caballero D
Bone Marrow Transplant; 2014 May; 49(5):684-90. PubMed ID: 24566710
[TBL] [Abstract][Full Text] [Related]
6. Hepatic veno-occlusive disease following sirolimus-based immune suppression.
Khimani F; McDonald GB; Shulman HM; Betts B; Locke F; Fernandez H; Anasetti C; Pidala J
Bone Marrow Transplant; 2019 Jan; 54(1):85-89. PubMed ID: 29895929
[TBL] [Abstract][Full Text] [Related]
7. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation.
Mirza AS; Tandon A; Jenneman D; Cao S; Brimer T; Kumar A; Kidd M; Khimani F; Faramand R; Mishra A; Liu H; Nishihori T; Perez L; Lazaryan A; Bejanyan N; Nieder M; Anasetti C; Pidala J; Elmariah H
Transplant Cell Ther; 2022 Apr; 28(4):185.e1-185.e7. PubMed ID: 35017119
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.
Kharfan-Dabaja MA; Parody R; Perkins J; Lopez-Godino O; Lopez-Corral L; Vazquez L; Caballero D; Falantes J; Shapiro J; Ortí G; Barba P; Valcárcel D; Esquirol A; Martino R; Piñana JL; Solano C; Tsalatsanis A; Pidala J; Anasetti C; Perez-Simón JA
Bone Marrow Transplant; 2017 Mar; 52(3):438-444. PubMed ID: 27819684
[TBL] [Abstract][Full Text] [Related]
9. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
[TBL] [Abstract][Full Text] [Related]
10. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.
Shayani S; Palmer J; Stiller T; Liu X; Thomas SH; Khuu T; Parker PM; Khaled SK; Forman SJ; Nakamura R
Biol Blood Marrow Transplant; 2013 Feb; 19(2):298-304. PubMed ID: 23078784
[TBL] [Abstract][Full Text] [Related]
11. Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus.
Rosenthal J; Pawlowska A; Bolotin E; Cervantes C; Maroongroge S; Thomas SH; Forman SJ
Pediatr Blood Cancer; 2011 Jul; 57(1):142-6. PubMed ID: 21557459
[TBL] [Abstract][Full Text] [Related]
12. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.
Pulsipher MA; Langholz B; Wall DA; Schultz KR; Bunin N; Carroll WL; Raetz E; Gardner S; Gastier-Foster JM; Howrie D; Goyal RK; Douglas JG; Borowitz M; Barnes Y; Teachey DT; Taylor C; Grupp SA
Blood; 2014 Mar; 123(13):2017-25. PubMed ID: 24497539
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
Huang B; Lin X; Zhang Z; Zhang Y; Zheng Z; Zhong C; He X; Chen M
Transplantation; 2020 Feb; 104(2):428-436. PubMed ID: 31283681
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
[TBL] [Abstract][Full Text] [Related]
15. Increased Infections and Delayed CD4
Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
17. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil.
Terakura S; Wake A; Inamoto Y; Murata M; Sakai R; Yamaguchi T; Takahashi S; Uchida N; Onishi Y; Ohashi K; Ozawa Y; Kanamori H; Yamaguchi H; Fukuda T; Ichinohe T; Takanashi M; Atsuta Y; Teshima T
Bone Marrow Transplant; 2017 Mar; 52(3):423-430. PubMed ID: 27941766
[TBL] [Abstract][Full Text] [Related]
18. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Hamilton BK; Liu Y; Hemmer MT; Majhail N; Ringden O; Kim D; Costa L; Stuart R; Alousi A; Pidala JA; Couriel DR; Aljurf M; Antin JH; Bredeson C; Cahn JY; Cairo M; Choi SW; Dandoy C; Gale RP; Gergis U; Hematti P; Inamoto Y; Kamble RT; MacMillan M; Marks DI; Nemecek E; Nishihori T; Saad A; Savani BN; Schriber J; Seo S; Socié G; Teshima T; Verdonck LF; Waller EK; Wirk M; Spellman SR; Arora M; Chhabra S
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1744-1755. PubMed ID: 31158502
[TBL] [Abstract][Full Text] [Related]
19. Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.
Abu Zaid M; Wu J; Wu C; Logan BR; Yu J; Cutler C; Antin JH; Paczesny S; Choi SW
Blood; 2017 Jan; 129(2):162-170. PubMed ID: 27827824
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia.
Onishi Y; Mori T; Yamazaki H; Takenaka K; Yamaguchi H; Shingai N; Ozawa Y; Iida H; Ota S; Uchida N; Miyamoto T; Katayama Y; Kato J; Yoshioka S; Onizuka M; Ichinohe T; Atsuta Y;
Ann Hematol; 2021 Jan; 100(1):217-228. PubMed ID: 33033911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
